On Monday, TriSalus Life Sciences, Inc. (NASDAQ: TLSI) received a positive outlook from Roth/MKM as the firm initiated coverage with a Buy rating and a price target of $11.00. The new coverage highlights TriSalus's innovative TriNav catheter, which utilizes Pressure Enabled Drug Delivery (PEDD) technology. The firm believes this technology is on track to become the standard for delivering therapeutics to liver tumors.
According to Roth/MKM, the PEDD technology has the potential to drive more than 50% growth for TriSalus by 2027. This growth projection is based solely on the current applications of the technology. The firm also noted the possibility of further clinical expansion beyond liver treatments, suggesting additional upside potential.
TriSalus is also working on expanding its platform through the integration of the TriNav catheter with a proprietary TL-9 antagonist. This combination is currently undergoing phase 1 evaluation and is expected to enhance the efficacy of the treatment. The analyst's comments underscore the company's innovative approach and the potential for significant growth in the medical technology sector.
The $11.00 price target set by Roth/MKM represents a vote of confidence in TriSalus's technology and its market potential. The company's focus on improving drug delivery to tumors with its PEDD technology is a key factor in the analyst's positive rating.
As TriSalus continues to develop its PEDD technology and expand its clinical applications, investors and the medical community will be watching closely. The initiation of coverage by Roth/MKM with a Buy rating and a notable price target is a significant development for the company as it strives to advance its position in the healthcare industry.
In other recent news, TriSalus Life Sciences has been experiencing a wave of positive analyst ratings. The company received an Outperform rating from both Northland and Oppenheimer, with Northland setting a price target at $12.50.
These ratings were based on the consistent sales growth of over 50% year-over-year that TriSalus's TriNav franchise has been delivering, and the potential of their TriNav system to become a standard of care for specific medical procedures.
Furthermore, the firm Jones Trading maintained a Buy rating for TriSalus, based on the anticipated clinical benefits of its product, Nelitolimod. Canaccord Genuity (TSX:CF) also held its Buy rating, emphasizing the company's growth prospects.
Recent developments in the company include the appointment of Dr. Riad Salem, a renowned expert in interventional radiology, to its Scientific Advisory Board and the addition of Liselotte Hyveled, a veteran in pharmaceutical research and development, to its Board of Directors.
TriSalus also reported a breakthrough in liver tumor treatment through its Pressure-Enabled Drug Delivery method, which demonstrated increased penetration compared to traditional methods.
Lastly, the company's revenue is annualizing at approximately $30 million with a compound annual growth rate of 40-50%, and it has secured a $50 million credit facility with healthcare investment firm OrbiMed, extending its financial runway through 2025.
InvestingPro Insights
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) presents a mixed financial picture that adds context to Roth/MKM's optimistic outlook. According to InvestingPro data, the company's revenue growth is impressive, with a 67.75% increase over the last twelve months as of Q2 2024. This aligns with the analyst's projection of over 50% growth by 2027. Additionally, TriSalus boasts a remarkable gross profit margin of 87.65%, which InvestingPro Tips highlight as "impressive gross profit margins."
However, investors should be aware of some financial challenges. An InvestingPro Tip notes that the company is "quickly burning through cash," which is reflected in its operating income margin of -212.06%. This suggests that while TriSalus is growing its revenue, it's doing so at a significant cost. Another InvestingPro Tip indicates that analysts do not anticipate the company will be profitable this year, which is consistent with the negative earnings per share of -$2.73 reported for the last twelve months.
Despite these challenges, TriSalus's market capitalization of $128.98 million and the fact that its stock has taken a significant hit over the last six months (-56.97% price return) could present an opportunity for investors who believe in the long-term potential of the company's PEDD technology.
For those interested in a deeper analysis, InvestingPro offers 8 additional tips for TLSI, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.